StockData

Ionis Pharmaceuticals vs Travere Therapeutics

IONS and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IONS and TVTX compare

Ionis Pharmaceuticals and Travere Therapeutics are about the same size, with market caps of $4.7B and $4.7B.

Travere Therapeutics grew revenue faster over the last twelve months (77.1% versus −7.4% for Ionis Pharmaceuticals).

Travere Therapeutics keeps more of each dollar of sales as profit, with a net margin of −7.4% compared with −64.7% at Ionis Pharmaceuticals.

Travere Therapeutics scores higher on the StockData Score (6 against 4 for Ionis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIONSTVTX
Size and price
Market cap$4.7B$4.7B
Share price$28.01$49.70
Change, 1 year−59.9%46.7%
Change, 5 years−3.6%71.2%
Beta (5Y)0.551.95
Employees1,402497
StockData Score
Total score46 (better)
Valuation score1 (better)0
Growth score23 (better)
Performance score02 (better)
Health score11
Dividend score00
Valuation
P/S5.3× (better)7.9×
P/B10.6× (better)191×
EV/EBITDA–192×
FCF yield−12.0%–
Fair value$28.16$6.04
Margin of safety0.55% (better)−723%
Growth
Revenue growth (TTM)−7.4%77.1% (better)
Revenue growth, 5Y average5.3%19.9% (better)
Profitability
Gross margin98.2%98.6% (better)
Operating margin−68.0%−6.8% (better)
Net margin−64.7%−7.4% (better)
FCF margin−64.2%–
Return on equity−105% (better)−152%
Financial health
Interest coverage−31.6×−4.3× (better)
Current ratio7.89 (better)4.05
Altman Z-score0.272.19 (better)
Piotroski F-score47 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions108%112%
Held by insiders0.81%1.6%
Insider net buying, 12 months−$114M−$110M (better)
Superinvestors holding1–
Short interest, % of float12.8%10.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.